Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD
Sponsor: Guangzhou Jiayin Biotech Ltd
Summary
VEGF inhibitors (anti-VEGF),such as aflibercept has been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients. EXG 202 is a recombinant adeno-associated virus (rAAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit.
Official title: A Phase I/II Clinical Study Evaluating the Safety and Preliminary Efficacy of EXG202 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-10-16
Completion Date
2032-12-30
Last Updated
2025-09-17
Healthy Volunteers
No
Conditions
Interventions
EXG202 injection
EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration(wAMD) with a single intravitreal injection and administration.